sub:assertion {
  d:DB01281 v:identifier "DB01281" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB01281" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB01281> ;
    dv:drugbank-id "DB01281" ;
    dv:x-ahfs <http://bio2rdf.org/ahfs:92:00.00> ;
    dv:x-atc <http://bio2rdf.org/atc:L04AA24> ;
    dv:x-cas <http://bio2rdf.org/cas:332348-12-6> ;
    dv:x-dpd <http://bio2rdf.org/dpd:2282097> ;
    dv:x-kegg <http://bio2rdf.org/kegg:D03203> ;
    dv:x-ndc <http://bio2rdf.org/ndc:0003-2187-10> ;
    dv:x-pharmgkb <http://bio2rdf.org/pharmgkb:PA164747080> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Abatacept> ;
    dct:description "Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each.  It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. Although approved for the treatment of rheumatoid arthritis, Repligen has entered a slightly different formulation of CTLA4-Ig into clinical trials (RG2077)."@en ;
    dct:identifier "drugbank:DB01281" ;
    dct:title "Abatacept"@en ;
    a dv:Drug ;
    rdfs:label "Abatacept [drugbank:DB01281]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB01281> , <http://www.drugs.com/cdi/abatacept.html> , <http://www.rxlist.com/cgi/generic/orencia.htm> .
}